Mast Cells and Basophils: A Potential Link in Promoting Angiogenesis during Allergic Inflammation

E. Crivellato\textsuperscript{a} L. Travan\textsuperscript{a} D. Ribatti\textsuperscript{b}

\textsuperscript{a}Division of Anatomy, Department of Medical and Morphological Research, University of Udine Medical School, Udine, and \textsuperscript{b}Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy

**Key Words**
Allergic inflammation · Angiogenesis · Basophils · Mast cells

**Abstract**
Mast cells and basophils are granulated metachromatic cells which possess complex and partially overlapping roles in acquired and innate immunity, including both effector and regulatory activities. Mast cells and basophils cooperate in exacerbating and/or modulating inflammation as well as in mediating subsequent tissue repair. Mast cells release a series of potent proangiogenic molecules during inflammation that stimulate vessel sprouting and new vessel formation. Recent data suggest that basophils may also play a role in inflammation-related angiogenesis, principally but not exclusively through the expression of several forms of vascular endothelial growth factors and their receptors. This review focuses on the potential cooperative link between mast cells and basophils in promoting angiogenesis during allergic inflammation. We discuss the multifaceted roles of mast cells and basophils in inflammatory mechanisms of allergic diseases and whether these cells can be both source and target of proangiogenic mediators.

**Introduction**
Mast cells and basophils represent distinct hematopoietic lineages that can express complementary or overlapping functions in the context of acute and chronic immunoglobulin E (IgE)-associated allergic responses [1, 2]. Recent work shows that mast cells and basophils also play a critical role in innate immunity to parasite and bacterial infection [3]. In addition, both cells can be activated by viral proteins [4, 5]. Mast cells have increasingly been implicated in the regulation and modulation of adaptive immune responses, in autoimmunity as well as in the expression of peripheral tolerance [2, 6]. Besides, mast cells contribute to non-immunological functions, such as tissue repair and remodelling, as well as tissue angiogenesis [7]. This review will discuss recent advances in understanding the potential cooperative link between mast cells and basophils, which may promote angiogenesis in the course of allergic inflammation.

**Natural History of Mast Cells and Basophils**

First described by the German pathologist Paul Ehrlich [8, 9], mast cells and basophils are granulated metachromatic cells, which share some phenotypic and functional properties but differ in important aspects of natural
history, mediator content, and function. Metachromatic staining of cytoplasmic granules primarily reflects their content of proteoglycans such as chondroitin sulfates (in basophils and mast cells) and heparin (in mast cells exclusively) [10]. Mast cells are tissue-resident cells originating from CD34+ hematopoietic stem cells and migrating into almost all of the major organs as immature committed progenitors [11]. Here, they complete their differentiation under the influence of tissue microenvironmental factors, in particular the stem cell factor, the ligand for the c-kit tyrosine kinase III growth factor receptor (secreted by fibroblasts, stromal cells and endothelial cells), which critically regulate many aspects of mast cell development and survival of human basophils in vitro and can induce basophil degranulation, a slow, particular and possibly selective mode of cell secretion mediated by vesicle transport of granule-stored material [14]. Basophils lack c-kit, they do not respond to stem cell factor. By contrast, their differentiation is crucially driven by interleukin (IL)-3, which promotes the production and survival of human basophils in vitro and can induce basophilia in vivo [14].

**Mast Cell and Basophil Mediators**

Following appropriate stimulation, mast cells and basophils release secretory products by anaphylactic degranulation (‘compound exocytosis’) or piecemeal degranulation, a slow, particular and possibly selective mode of cell secretion mediated by vesicle transport of granule-stored material [10]. Mediators are either preformed and granule associated or are synthesized de novo. Major mediators stored preformed in mast cell granules are histamine, heparin, serine proteases such as tryptase and chymase, cathepsin G, peroxidase, many acidic hydrolases, carboxypeptidases and antimicrobial peptides such as cathelicidins [15]. Basophil granules contain less amounts of histamine, lack heparin but contain proteoglycans like chondroitin sulfates and Charcot-Leyden crystal protein. Mouse but not human basophil granules express TSLP (thymic stromal lymphopoietin) [16]. A human basophil-specific protein, basogranulin, is released upon cell degranulation [17]. In some allergic patients, circulating basophils may contain tryptase, chymase and carboxypeptidase A, and express the c-kit receptor, which is normally absent on the surface of basophils, suggesting that these cells may modulate their phenotype [18]. Proinflammatory lipid mediators de novo synthesized and released by mast cells include prostaglandins (PGE\(_2\) and PGD\(_2\)), cysteinyl leukotrienes (LTB\(_4\) and LTC\(_4\)) and platelet-activating factor [15]. By contrast, LTC\(_4\) and platelet-activating factor are the only identified lipid mediators released by basophils [16]. Both mast cells and basophils synthesize and release an array of growth factors, cytokines and chemokines involved in inflammation, immunity, hematopoiesis, tissue remodelling and other biological functions. Human and mouse mast cells secrete tumor necrosis factor (TNF-\(\alpha\)), transforming growth factor (TGF)-\(\beta\), fibroblast growth factor (FGF)-2, vascular endothelial growth factor (VEGF), granulocyte macrophage-colony stimulating factor (GM-CSF), nerve growth factor (NGF), platelet-derived growth factor, interferon-\(\alpha\), -\(\beta\) and -\(\gamma\), many ILs (IL-1\(\alpha\), IL-1\(\beta\), IL-3, IL-4, IL-5, IL-6, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-16, IL-18 and IL-25), and several C-C and CXC chemokines, including monocyte chemotactic protein (MCP)-1 (CCL2) and macrophage inflammatory protein-1\(\alpha\) (CCL3). IL-8 (CXCL-8) has chemokine functions as well [15]. By contrast, basophils secrete a restricted array of products such as VEGF, IL-4, IL-6 and IL-13 [19]. These data suggest that mast cells and basophils can participate in intricate paracrine and autocrine networks that may contribute to leukocyte recruitment, stromal and tissue cell activation, modulation of immune functions, tissue remodelling and angiogenesis [20].

**Immunological Functions of Mast Cells and Basophils**

Both mast cells and basophils express the tetrameric \(\alpha\)\(\beta\)\(\gamma\)_\(\gamma\) \(\beta\)-form of the high-affinity receptor FceRI for IgE on their surface and both kinds of cells are crucial effectors in T-helper 2 (Th2) cell-dependent, IgE-associated allergic disorders and immune responses to parasites [21–23].
Mast Cells and Basophils in Inflammatory Angiogenesis

The cross-linking of IgE bound to the high-affinity receptor FcεRI with bivalent or multivalent antigen results in the aggregation of FcεRI on the surface of these cells, which is sufficient for initiating downstream signal transduction events that activate cell degranulation as well as de novo synthesis and secretion of lipid mediators and cytokines [24]. Binding of IgE to FcεRI not only regulates mast cell and basophil functions but might directly or indirectly influence cellular survival and resistance to apoptosis [25]. In addition, both mast cells and basophils can be activated by IgG-mediated mechanisms [26, 27] as well as G protein-coupled receptor and Toll-like receptor activation mechanisms [3, 28, 29]. Mediators released by mast cells and basophils have effector, immunoregulatory or autocrine effects that profoundly influence the orchestration of allergic inflammation. Beyond influencing immune responses via the secretion of cytokines, in vitro experiments suggest that human mast cells and basophils can function as antigen-presenting cells and/or represent sources of costimulatory activity (e.g. by expressing CD40 or its ligand) [30, 31].

Mast cells and basophils also participate in host defense against bacteria, viruses, fungi and parasites [32]. Besides releasing biologically potent mediators, mast cells express a wide spectrum of surface receptors for cytokines, chemokines and bacterial products [33]. This enables mast cells to perform crucial functions in the context of either acquired or innate immune responses. It is now clear that mast cells are involved in a variety of pathological settings, including autoimmunity [6]. Interestingly, mast cells express either beneficial or detrimental effects in a number of physiological and pathological processes. Murine mast cells, for instance, provide a crucial life-saving role in experimental bacterial infections. In genetically mast cell-deficient W/W V mice, mast cells exert a fundamental protective role in a model of acute septic peritonitis following cecum ligation and puncture, and in a model of enterobacteria inocula [34, 35]. This protective effect is mainly due to the release of TNF-α, but other mast cell-derived products, such as cathelicidins and chymase, may have direct bactericidal activity or degrade toxic peptides [3]. In a recent study, mast cells reduced neurotensin-related mortality in a mouse model of sepsis [36]. Thus, mast cells may behave as vital sentinels that orchestrate potent inflammatory reactions against different microorganisms, linking innate immunity with the adaptive immune system. On the other hand, they play a critical role in initiating or aggravating disease in models of rheumatoid arthritis, multiple sclerosis, bullous pemphigoid and atherosclerosis in mice [37]. Mast cells and basophils may possess similar or overlapping functions in immunity against parasites. Parasite infections are often associated with increased levels of circulating basophils, increased serum levels of IgE, and increased numbers of mast cells and/or basophils in the affected tissues both in man and mice [22]. Human mast cells and basophils may be activated by bacterial superantigens, such as protein L of *Pneumococcus magnus*, protein A of *Staphylococcus aureus*, the Hp(2-20)-derived peptide from *Helicobacter pylori* and viral antigens, and HIV glycoprotein 120 (gp120), which interact with distinct regions of IgE, inducing mediator release from these cells [4, 5, 38].

From Acute Allergic Reaction to Chronic Allergic Inflammation

Mast cells and basophils are key effector cells in initiating and/or amplifying IgE-dependent inflammatory reactions [15, 39]. In addition, they also express immunoregulatory functions in the same settings [1, 2, 20, 40]. Both mast cells and basophils are activated during IgE-associated anaphylaxis. Anaphylaxis is an acute-phase, potentially fatal systemic allergic reaction that can be triggered by immunological or non-immunological mechanisms [41]. IgE plays a crucial role in the immediate hypersensitivity response through binding with the high-affinity receptor FcεRI, but other IgE-independent mechanisms, such as G protein-coupled receptor and Toll-like receptor activation processes, may intervene [42, 43]. Activated mast cells and basophils release Th2 cytokines (IL-4, IL-5, IL-9 and IL-13) that polarize the immune reaction, and produce various bioactive chemical mediators, such as histamine and lipid metabolites, that provide vasoactive, chemotactic and immunoregulatory functions [44, 45]. Remarkably, during inflammation, both human and mouse basophils release considerable amounts of IL-4 very rapidly, thus they may have a critical impact on the outcome of a primary infection [13, 20, 46].

In addition to their roles in classic acute IgE-associated immediate hypersensitivity responses, several lines of evidence indicate that mast cells and basophils can also contribute to late-phase and chronic allergic reactions [39, 47–49]. Mast cells have been shown to change their degranulation pattern from acute to chronic allergic responses [50]. Anaphylactic degranulation is triggered by IgE-dependent and neuropeptide activation mainly during the early phase of allergic reactions [39]. Differential release without degranulation is activated by mediators
such as IL-1 (in humans), stem cell factor (in mice), lipopolysaccharide (in rats) and corticotropin-releasing hormone (in humans), and classically occurs during chronic inflammatory diseases [50, 51]. Many clinical symptoms of IgE-dependent late-phase reactions, in the respiratory and gastrointestinal tract and in the skin, reflect the actions of leukocytes recruited to these sites by mast cells and basophils. Cytokines (TNF-α, IL-6 and IL-8) and neutral proteases, as well as histamine and lipid mediators, may contribute to mast cell- and basophil-dependent leukocyte recruitment – in particular eosinophil recruitment – in such settings [52]. Leukocytes, in turn, exacerbate the inflammatory reaction by providing additional proinflammatory mediators and cytokines (‘mast cell-leukocyte cytokine cascade’). In the course of chronic allergic inflammation in humans, the cellular infiltrates present in the skin, upper airways and lungs are similar in composition and characterized by prominent eosinophils and T cells, with smaller numbers of monocytes, macrophages and mast cells [39, 53–55]. Basophils are also recruited to late-phase reaction sites such as the skin, nose and lower airways in humans [56]. Certain mast cell cytokines, such as TNF-α, VEGF, FGF-2 and TGF-β, contribute to chronic allergic inflammation through effects on fibroblasts, vascular endothelial cells and other cells resident at the sites of these reactions [39]. Persistent chronic allergic inflammation can result in remodelling of the affected tissues, and these structural changes are often associated with activation of the angiogenic process [47]. Indeed, airway tissues from patients with asthma characteristically show blood vessel proliferation in the mucosa and submucosa besides infiltration of the submucosa and epithelium by mast cells, basophils, T cells and eosinophils, epithelial thickening, smooth muscle cell hypertrophy, mucous gland hyperplasia, and collagen and tenascin deposition beneath the epithelial basement membrane [47].

**Inflammation and Angiogenesis**

Angiogenesis, i.e. the formation of new blood vessels from the preexisting vasculature, is a multistep complex phenomenon crucial for numerous inflammatory and immune disorders, including allergic diseases [57]. In 1960, Dunnill [58] demonstrated for the first time that asthmatic subjects who succumb acute attacks have an enlarged capillary bed in the airway wall. Later on, increased vascularity in the airways has been recognized not only in patients with severe asthma, but also in those with mild disease [59, 60]. The major structural and functional changes in the airway microcirculation include the proliferation of new vessels, increased vascular areas of medium and small airways, increased blood flow and microvascular permeability, and edema formation in the airway wall [61, 62].

Cytokines of the CXC family play a pivotal role in the control of inflammation and angiogenesis since their specific receptors do not differ from those expressed on leukocytes and endothelial cells [63]. Thus, CXC chemokines are not only responsible for leukocyte recruitment to inflamed tissues, they also regulate the inflammatory reaction leading to angiogenesis, tissue repair and new tissue generation [64–66]. Recent evidence indicates that endothelial cells express specific CXC receptors (CXCR), such as CXCR1, CXCR2, CXCR3 and CXCR4, which induce endothelial cell chemotaxis and form blood vessels [67].

Human mast cells and basophils are endowed with a wide set of chemokine receptors. Basophils constitutively express CCR1, CCR2, CCR3, CXCR1, CXCR3 and CXCR4 [20, 45]. CCR3 is highly expressed on human basophils and can be activated by eotaxin (CCL11), RANTES (CCL5), MCP-3 (CCL7) and MCP-4 (CCL13) [68]. In contrast to human basophils, mouse basophils do not express CCR3. Interestingly, CCR3 is also expressed by about 25% of lung mast cells in subjects with bronchial asthma [69]. Upon IgE overproduction, mouse basophils release CCL22, a potent chemoattractant for Th2 cells which has been implicated in Th2-predominant allergic inflammation [70].

Mast cells and basophils are a major source of several angiogenic factors and display their receptor counterparts on their membrane, thus influencing angiogenesis during allergic inflammation (fig. 1). Both mast cells and basophils synthesize and release VEGF, the most potent proangiogenic mediator known so far [71, 72]. Murine mast cells lacking JunB, a member of the AP-1 transcription factor family regulating IgE-mediated mast cell degranulation, severely impair in vitro angiogenesis due to inhibition of VEGF secretion [73]. Human mast cells, however, are a potent source of VEGF in the absence of degranulation through activation of the EP2 receptor by PGE2 [74]. Selective release of VEGF by human mast cells is regulated by corticotropin-releasing hormone [75]. VEGF is also produced by human basophils [72]. Basophils express mRNA for various members of the VEGF family. Peripheral blood and basophils infiltrating sites of chronic inflammation, e.g. nasal polyps, contain VEGF-A in their secretory granules. In addition, human basophils express the tyrosine kinase VEGF-A receptor VEGFR-2/KDR, and neuropilin-1, which acts as a core-
ceptor for VEGFR-2/KDR and enhances VEGFR-2-induced responses. Remarkably, VEGF-A also functions as basophil chemoattractant providing a novel autocrine loop for basophil self-recruitment. Both mast cells and basophils release histamine, which displays angiogenic activity in several in vitro and in vivo settings [76]. Mast cells synthesize and release other potent angiogenic cytokines, e.g. FGF-2, the serine proteases tryptase and chymase, IL-8, TGF-β, TNF-α and NGF [50]. Recently, mast cells from human uterine leiomyomas have been found to contain leptin, a 167-amino-acid residue peptide mainly secreted by adipocytes which, besides its involvement in obesity development, expresses angiogenic activity [77]. In addition, human skin, lung and synovial mast cells contain matrix metalloproteinase-9, which degrades the extracellular matrix, thus releasing angiogenic factors bound to the extracellular matrix [78].

Mast Cell and Basophil Cross-Talk in Inflammatory Angiogenesis

Mast cells and basophils also participate in inflammation, along with other blood-borne and tissue-resident cells involved in different allergic reactions. These cells cooperate in the exacerbation and/or modulation of inflammation as well as in mediating tissue remodelling and angiogenesis [79]. Many mediators and receptors are involved in such paracrine and autocrine signaling (fig. 2). Human basophils express the seven-transmembrane receptor CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) whose activation by mast cell-released PGD₂ induces basophil chemotaxis [80]. Basophil-released histamine, in turn, may potentiate mast cell chemotaxis at sites of inflammation via interaction with the H₄ receptor [81]. Interestingly, mast cell- and basophil-released histamine downregulates basophil responses by inhibiting the release of mediators from human basophils via the H₂ receptor [82]. Cysteinyl leukotrienes produced by immunologically activated mast cells and basophils exert a variety of responses by activating the receptors CysLTR₁ and CysLTR₂, which are expressed, among other cells, by mast cells and basophils themselves [83, 84]. IL-4 and LTC₄, secreted by mast cells and basophils, upregulate the expression of CysLTR₁ and stimulate LTC₄ and cytokine production by human mast cells. MCP-1 (CCL2) secreted by mast cells may induce stimulation of histamine and leukotriene release from human basophils and mast cells themselves [85]. Both human mast cells and basophils release VEGF,
which is the most potent inducer of endothelial cell proliferation, migration, survival and tube formation [71, 72]. VEGF also presents proinflammatory cytokine functions and, remarkably, acts on basophils as chemoattractant [72]. So, mast cell-released VEGF concurs with basophil recruitment at inflammatory sites. Interestingly, human basophils express a number of receptors for growth factors released by mast cells, e.g. IL-2R, IL-3R, IL-4R, IL-5R, GM-CSF-R, NGF-R and IL-8 (CXCL-8) [86]. Cytokines such as IL-3, IL-5, IL-8 and GM-CSF have been associated with the tissue influx and subsequent activation of human basophils [13]. In addition, both human mast cells and basophils express the high-affinity urokinase plasminogen activator (uPA) receptor (uPAR) [87, 88], a potent chemoattractant for both kinds of cells, and, remarkably, uPA and uPAR are involved in tissue remodelling and vessel sprouting [88, 89].

Concluding Remarks

Human mast cells and basophils are conventionally considered primary effector cells in different allergic conditions such as bronchial asthma. We feel that it is too soon to conclude whether and to what extent mast cells and basophils are involved in tissue remodelling associated with allergic inflammation. However, several lines of evidence suggest that mast cells and basophils may contribute to this process. These cells produce several mediators and express surface receptors that provide the basis for complex paracrine and autocrine cross-talking networks. In addition, mast cell- and basophil-derived secretory products express a number of in vitro or in vivo effects that are consistent with the hypothesis that both cells can cooperate in promoting tissue neovascularization during allergic inflammation. Thus, these cells can be both source and target for proangiogenic mediators.
Angiogenesis is a critical step in the perpetuation of allergic inflammation via the release of VEGF and other angiogenic mediators. Thus, strategies directed to downregulate VEGF production might be of benefit in the treatment of allergic diseases.

Acknowledgment

This study has been supported by local funds from the Ministry of Education, University and Research (MIUR) to the Division of Anatomy, Department of Medical and Morphological Research, University of Udine.

References


Mast Cells and Basophils in Inflammatory Angiogenesis

Int Arch Allergy Immunol 2010;151:89–97


Mast Cells and Basophils in Inflammatory Angiogenesis


83 Mellor EA, Maekawa A, Austen KF, Boyce JA: Cysteinyl leukotriene receptor 1 is also a pyrimidinergic receptor and is expressed by human mast cells. Proc Natl Acad Sci USA 2001;98:7964–7969.


